Trial Profile
A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of BI655130 (SPESOLIMAB) Induction Therapy in Patients With Moderate-to-severely Active Ulcerative Colitis Who Have Failed Previous Biologics Therapy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 15 Dec 2021
Price :
$35
*
At a glance
- Drugs Spesolimab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharma KG
- 28 Jun 2020 This trial has been Discontinued in Netherlands according to European Clinical Trials Database record.
- 18 Jun 2020 This trial has been Completed in United Kingdom according to European Clinical Trials Database record.
- 01 Jun 2020 This trial has been Discontinued in Spain according to European Clinical Trials Database record.